Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 11, 2009

Genentech and Biogen Idec Report Positive Late-Stage Data with RA Therapy

  • A Phase III trial has found that combining Genentech and Biogen Idec’s humanized anti-CD20 antibody ocrelizumab with methotrexate effectively reduces the signs and symptoms of rheumatoid arthritis in sero-positive patients who previously demonstrated inadequate responses to methotrexate alone.

    The companies say the international Phase III STAGE trial was the first to evaluate ocrelizumab in combination with methotrexate in this population of patients. The co-primary endpoint was an improvement in the signs and symptoms of RA at week 24 and week 28 in comparison with methotrexate monotherapy. 

    Results from three additional Phase III trials evaluating ocrelizumab in rheumatoid arthritis patients are due during the first half of 2010. Data from a Phase III trial evaluating ocrelizumab in patients with lupus nephritis are expected in 2011.

    In June an arbitration panel ruled on a dispute between Genentech and Biogen Idec, relating to decision-making rights and other disagreements for anti-CD20 products covered by the companies’ collaboration agreement, including Rituxan, which Biogen Idec co-promotes in the U.S.


Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »